secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628908-26-000031
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Evolent Health Reports Q1 2026 Results; Revenue Up, Net Loss Narrowed
---------------------------------------------------------------------

- Revenue $496.2M vs $483.6M in Q1 2025; net loss improved to $26.6M from $72.3M.
- Adjusted EBITDA $22.1M with margin 4.4%, down from $36.9M margin 7.6% prior year.
- Signed new revenue agreements: advanced imaging solution for ~4.5M lives; oncology/cardiology expansion expected >$200M annual revenue.
- CEO Seth Blackley highlighted successful oncology launches at Highmark and Aetna, focus on AI opportunity.
- Medical expense ratio rose to 93.3% from 68% (84% excluding Evolent Care Partners).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/0001628908-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/evh-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628908-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer